Company Overview
Thyrocare Technologies Limited reported strong financial and operational performance for FY 2025-26, with consolidated revenue of ₹829.04 crore (20.61% YoY growth) and profit after tax of ₹162.85 crore (79% YoY growth). The company processed 209.6 million tests and served 19.2 million patients, expanding its laboratory network to 41 facilities including international presence in Tanzania.
Financial Performance
Consolidated Results: Revenue ₹829.04 crore (up 21% YoY), PAT ₹162.85 crore (up 79% YoY), EBITDA ₹256 crore (34% growth), EBITDA margin 31.6% (400 bps improvement). Standalone Results: Revenue ₹774.27 crore (up 22% YoY), PAT ₹148.81 crore (up 55% YoY). The company maintained strong cash flow from operations of ₹206.07 crore.
Corporate Actions & Capital Structure
The company issued bonus shares in 2:1 ratio and paid total dividends of ₹148.43 crore, including an interim dividend of ₹7 per share and recommended final dividend of ₹7 per share. Authorized share capital was increased from ₹100 crore to ₹300 crore, with paid-up capital at ₹159.17 crore as of March 31, 2026.
Operational Highlights
Thyrocare expanded its test menu to 1,275+ tests, launched new services in allergy testing, genomics, and women's health diagnostics. International operations in Tanzania generated ₹2.73 crore revenue with planned scaling in FY27. The company implemented significant technology upgrades including AI-powered phlebotomy audits and AWS cloud migration.
Subsidiaries & Acquisitions
Subsidiary Performance: Nueclear Healthcare (revenue ₹44.62 crore, PAT ₹6.16 crore), Think Health Diagnostics (revenue ₹0.01 crore, PAT ₹0.21 crore), Thyrocare Tanzania (revenue ₹2.73 crore, PAT -₹4.53 crore). Acquisitions: Polo Labs (₹4.26 crore) and Vimta Labs (₹7.00 crore) diagnostic businesses were acquired, contributing to portfolio expansion.
Governance & Management Changes
Board composition included 9 Directors with several changes: Mr. Hardik Kishor Dedhia resigned as Director, Mr. Alok Kumar Jagnani transitioned from CFO to Non-Executive Director, and Mr. Vikram Gupta appointed as CFO. Post-FY26, Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah stepped down, with Mr. Gaurav Verma and Mr. Uday Patel Kadam appointed as Directors.
Regulatory & Tax Matters
The company faces pending tax disputes totaling ₹8.82 crore across various assessment years, including GST and income tax matters. Auditors provided unqualified opinions on both standalone and consolidated financial statements, confirming adequate internal financial controls with no material frauds reported.
Related Party Transactions
Material transactions with holding company Docon Technologies Private Limited totaled ₹101.88 crore, including diagnostic services of ₹75.09 crore. Prior shareholder approval was obtained for these transactions. Key management personnel compensation totaled ₹8.08 crore.
26th Annual General Meeting
The AGM will be held on June 30, 2026, to approve financial statements, declare final dividend, appoint M/s. Price Waterhouse as statutory auditors for 5 years, and approve related party transactions with Docon Technologies. Record date for dividend is June 23, 2026.
Risk Factors & Forward Outlook
Key risks include intense competition in fragmented market, reputational risk from report inaccuracies, technological disruption, skilled workforce attrition, and international operations risks. The company maintains positive outlook with continued expansion and portfolio diversification strategies.